Tyrosine-protein kinase SYK

HUTCHMED Initiates a Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Retrieved on: 
Monday, October 10, 2022

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China.

Key Points: 
  • HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Oct. 10, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ( HUTCHMED ) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has initiated a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China.
  • The Phase II stage of the study is to evaluate the safety and preliminary efficacy of sovleplenib in adult patients with wAIHA.
  • If results of the Phase II stage are positive, the Phase III stage will be initiated to confirm such efficacy and safety.
  • Sovleplenib is a novel, investigational, selective small molecule inhibitor for oral administration targeting the spleen tyrosine kinase, also known as Syk.

Spleen Tyrosine Kinase Inhibitors Pipeline Market Research Report 2022 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 31, 2022

The "Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Spleen tyrosine kinase inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Spleen tyrosine kinase inhibitors pipeline landscape.
  • Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells.
  • The companies which have their Spleen tyrosine kinase inhibitors drug candidates in the most advanced stage, i.e.

BioFlux System Used in Key Studies to Identify Causes and Treatments of Blood Clots Related to COVID-19

Retrieved on: 
Thursday, January 27, 2022

Although predominantly a respiratory disease, COVID-19 has been shown to cause a range of responses, including adverse effects on the cardiovascular system.

Key Points: 
  • Although predominantly a respiratory disease, COVID-19 has been shown to cause a range of responses, including adverse effects on the cardiovascular system.
  • Both papers relied on the BioFlux system to assess platelet function in COVID-19 patients.
  • Used in more than 500 labs globally, the BioFlux system is available in a variety of configurations to meet the application requirements of any laboratory.
  • Systems are available with a range of capabilities and throughputs and are used in basic research through drug discovery and diagnostic development.

HUTCHMED Receives Breakthrough Therapy Designation in China for HMPL-523 for Treatment of Primary Immune Thrombocytopenia

Retrieved on: 
Wednesday, January 12, 2022

Drug candidates with BTD may be considered for conditional approval and priority review when submitting a New Drug Application (NDA).

Key Points: 
  • Drug candidates with BTD may be considered for conditional approval and priority review when submitting a New Drug Application (NDA).
  • The granting of BTD to HMPL-523 in ITP highlights the unmet need in this treatment setting and the promising clinical value of this novel oral Syk inhibitor.
  • With this designation, we are hopeful that can accelerate the development of HMPL-523 in China.
  • The data also supported the initiation of a Phase III trial, ESLIM-01, in China of HMPL-523 in adult patients with ITP in October 2021.

HUTCHMED Highlights HMPL-523 Clinical Data Presented at the 2021 ASH Annual Meeting

Retrieved on: 
Tuesday, December 14, 2021

As of data cutoff date of August 25, 2021, 21 patients received a median of two cycles of treatment (range: 1-19).

Key Points: 
  • As of data cutoff date of August 25, 2021, 21 patients received a median of two cycles of treatment (range: 1-19).
  • Among 16 response-evaluable patients, 4 responses were seen in patients in the 400-800 mg cohorts totaling 10 patients.
  • Among 21 enrolled patients, 17 (81.0%) patients experienced TRAEs, including 7 (33.3%) who experienced grade 3 or above TRAEs.
  • HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

HUTCHMED Highlights HMPL-523 Clinical Data to be Presented at the 2021 ASH Annual Meeting

Retrieved on: 
Monday, November 8, 2021

HMPL-523 is also being studied in indolent non-Hodgkins lymphoma and multiple subtypes of B-cell malignancies in China ( NCT02857998 ), the U.S. and Europe ( NCT03779113 ).

Key Points: 
  • HMPL-523 is also being studied in indolent non-Hodgkins lymphoma and multiple subtypes of B-cell malignancies in China ( NCT02857998 ), the U.S. and Europe ( NCT03779113 ).
  • A trial to study HMPL-523 in patients with warm autoimmune hemolytic anemia (wAIHA), another autoimmune disorder, is also planned.
  • HMPL-306 is an investigative and selective small molecule inhibitor of IDH1 and IDH2, and the companys sixth novel oncology candidate to enter global clinical development.
  • HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

HUTCHMED Initiates ESLIM-01, a Phase III Trial of HMPL-523 in Patients with Immune Thrombocytopenia in China

Retrieved on: 
Thursday, October 28, 2021

The study is a randomized, double blinded, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of HMPL-523 in treating adult patients with ITP.

Key Points: 
  • The study is a randomized, double blinded, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of HMPL-523 in treating adult patients with ITP.
  • We hope HMPL-523 will provide an important alternative that can induce durable response for patients in this treatment setting.
  • The rationale for this Phase III study is based on encouraging data from the Phase Ib study of HMPL-523 in adult patients with ITP.
  • A trial to study HMPL-523 in patients with warm autoimmune hemolytic anemia (wAIHA), another autoimmune disorder, is also planned.

Kronos Bio Announces Participation in Upcoming Investor Conferences

Retrieved on: 
Wednesday, May 26, 2021

The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .

Key Points: 
  • The fireside chats will be webcast live from the Investors & Media section of the companys website at www.kronosbio.com .
  • Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • Kronos Bio is developing a portfolio of spleen tyrosine kinase (SYK) inhibitors, entospletinib (ENTO) and lanraplenib (LANRA), for the treatment of NPM1-mutated and FLT3-mutated acute myeloid leukemia (AML).
  • Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass.

Kronos Bio Reports Recent Business Progress and First Quarter Financial Results and Announces Virtual R&D Day

Retrieved on: 
Tuesday, May 11, 2021

\xe2\x80\x9cWe recently showcased progress with our CDK9 program at the AACR annual meeting in April, where we presented preclinical data indicating that KB-0742 could have utility in the treatment of MYC-amplified cancers.

Key Points: 
  • \xe2\x80\x9cWe recently showcased progress with our CDK9 program at the AACR annual meeting in April, where we presented preclinical data indicating that KB-0742 could have utility in the treatment of MYC-amplified cancers.
  • We look forward to sharing more about our development plans for this compound at our research and development day.\xe2\x80\x9d\nDr.
  • The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth.
  • Kronos Bio\xe2\x80\x99s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).

Kronos Bio Announces Participation in Bank of America Securities 2021 Health Care Conference

Retrieved on: 
Thursday, May 6, 2021

A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.

Key Points: 
  • A replay of the webcast will be archived and available for one month following the event.\nKronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering and developing therapies that seek to transform the lives of those affected by cancer.
  • The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth.
  • Kronos Bio\xe2\x80\x99s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML).
  • For more information, visit www.kronosbio.com or follow the company on LinkedIn .\n'